1.Can we predict neonatal thrombocytopenia in offspring of women with idiopathic thrombocytopenic purpura?.
Kazuhisa HACHISUGA ; Nobuhiro HIDAKA ; Yasuyuki FUJITA ; Kotaro FUKUSHIMA ; Kiyoko KATO
Blood Research 2014;49(4):259-264
BACKGROUND: We aimed to investigate which factors in the clinical profile of mothers with idiopathic thrombocytopenic purpura (ITP) can predict neonatal risk of thrombocytopenia. METHODS: Data was retrospectively collected from all pregnant women with ITP who presented to our institution between 2001 and 2013. Neonatal offspring of these women were classified into 2 groups based on the presence or absence of neonatal thrombocytopenia (platelet count <100x109/L). Several parameters were compared between the 2 groups, including maternal age, maternal platelet count, maternal treatment history, and thrombocytopenia in siblings. We further examined the correlation between maternal platelet count at the time of delivery and neonatal platelet count at birth; we also examined the correlation between the minimum platelet counts of other children born to multiparous women. RESULTS: Sixty-six neonates from 49 mothers were enrolled in the study. Thrombocytopenia was observed in 13 (19.7%) neonates. Maternal treatment for ITP such as splenectomy did not correlate with a risk of neonatal thrombocytopenia. Sibling thrombocytopenia was more frequently observed in neonates with thrombocytopenia than in those without (7/13 vs. 4/53, P<0.01). No association was observed between maternal and neonatal platelet counts. However, the nadir neonatal platelet counts of first- and second-born siblings were highly correlated (r=0.87). CONCLUSION: Thrombocytopenia in neonates of women with ITP cannot be predicted by maternal treatment history or platelet count. However, the presence of an older sibling with neonatal thrombocytopenia is a reliable risk factor for neonatal thrombocytopenia in subsequent pregnancies.
Child
;
Female
;
Humans
;
Infant, Newborn
;
Maternal Age
;
Mothers
;
Parturition
;
Platelet Count
;
Pregnancy
;
Pregnant Women
;
Purpura, Thrombocytopenic, Idiopathic*
;
Retrospective Studies
;
Risk Factors
;
Siblings
;
Splenectomy
;
Thrombocytopenia
;
Thrombocytopenia, Neonatal Alloimmune*
2.Gastric cancer during pregnancy with placental involvement: case report and review of published works
Seiya OGA ; Masahiro HACHISUGA ; Nobuhiro HIDAKA ; Yasuyuki FUJITA ; Hiroshi TOMONOBE ; Hidetaka YAMAMOTO ; Kiyoko KATO
Obstetrics & Gynecology Science 2019;62(5):357-361
Gastric cancer involving the placenta during pregnancy is rare; however, we present 1 such case in this report. A 31-year-old Japanese woman was referred at 26 weeks of gestation for the evaluation of a swollen left supraclavicular lymph node. Biopsy revealed poorly differentiated adenocarcinoma, and esophagogastroduodenoscopy with biopsy of the stomach confirmed the diagnosis of gastric cancer. Her epigastric and back pain became more pronounced and her general status worsened, and we performed a cesarean delivery at 29 weeks. Microscopic examination of the placental specimen revealed poorly differentiated adenocarcinoma cells diffused into the intervillous space. Postpartum chemotherapy consisted of S-1 plus oxaliplatin. Unfortunately, this treatment was ineffective, and the patient died 3 months after delivery. The infant did well, without clinical or laboratory manifestations of metastasis. In patients with advanced gastric cancer during pregnancy, it is important to perform a microscopic examination of the placenta to evaluate for metastatic involvement.
Adenocarcinoma
;
Adult
;
Asian Continental Ancestry Group
;
Back Pain
;
Biopsy
;
Diagnosis
;
Drug Therapy
;
Endoscopy, Digestive System
;
Female
;
Humans
;
Infant
;
Lymph Nodes
;
Neoplasm Metastasis
;
Placenta
;
Postpartum Period
;
Pregnancy
;
Stomach
;
Stomach Neoplasms